一、公司不存在法律、法规和规范性文件规定的不得实施股权激励的情形; 公司未发生《浙江康恩贝制药股份有限公司 2022年股票期权激励计划(草案)》 中规定的不得行权的情形。经确认,公司层面本次激励计划首次授予股票期权第 二个行权期和授予预留股票期权第一个行权期的行权条件已成就。 二、有关本次激励计划可行权激励对象的核查情况为: 浙江康恩贝制药股份有限公司 关于 2022 年股票期权激励计划可行权激励对象名单的 核 查 意 见 浙江康恩贝制药股份有限公司(以下简称"公司")监事会根据《公司法》、 《上市公司股权激励管理办法》(以下简称"《管理办法》")和《公司章程》等有 关规定,对公司 2022年股票期权激励计划(以下简称"本次激励计划")可行权 激励对象名单进行了核查,并发表核查意见如下: 2 (一)首次授予股票期权的 488 名激励对象中,除 27 名人员因退休、离职 等原因不再具备激励对象资格和行权条件,以及第二个考核年度(2023年度)中 有 7 名激励对象个人层面绩效考核结果为"合格"、其个人层面行权比例为 80%， 有 1 名激励对象个人层面绩效考核结果为"不合格"、其个人层面行权比例为 0% 外,其 ...

会议审议了有关议案，经书面表决通过决议如下： 一、审议通过《关于注销 2022 年股票期权激励计划部分股票期权的议案》。表决 情况：同意 3 票，反对 0 票，弃权 0 票。 经审核，监事会认为：鉴于截至目前，公司 2022 年股票期权激励计划的激励对 象中有人员因退休、离职等原因不再具备激励对象资格和行权条件，以及经统计首次 授予股票期权第二个行权期、预留授予股票期权第一个行权期对应考核年度激励对象 个人层面绩效考核结果（不能 100%行权的情形），同意注销以上激励对象已获授但不 得行权的股票期权共计 202.92 万份。公司注销上述股票期权符合相关规定，不存在 损害公司及股东利益的情形。 证券代码：600572 证券简称：康恩贝 公告编号：临 2025-058 浙江康恩贝制药股份有限公司 第十一届监事会第十次（临时）会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称"公司"）第十一届监事会第十次（临 时）会议于 2025 年 11 月 6 日以通讯方式召开。会议通知于 202 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2025-057 浙江康恩贝制药股份有限公司 十一届董事会第十二次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司(以下简称"公司")第十一届董事会第十二次（临时） 会议于 2025 年 11 月 6 日以通讯方式召开。会议通知于 2025 年 10 月 31 日以书面、传 真、电子邮件方式送达各董事。会议应参加审议表决董事 9 人，实际参加审议表决董事 9 人。公司监事以审议有关议案方式列席会议。会议的召开符合《公司法》《公司章程》 的规定。 会议审议了有关议案，经书面表决通过决议如下： 一、审议通过《关于注销 2022 年股票期权激励计划部分股票期权的议案》。表决情 况：同意 7 票，回避 2 票，反对 0 票，弃权 0 票。（详见同日刊登于上海证券交易所网 站 www.sse.com.cn 和《中国证券报》《上海证券报》《证券时报》的公司临 2025—059 号《关于注销 2022 年股票期权激励计划部分股票期权的公告 ...

第十一届董事会薪酬与考核委员会 2025年第三次会议决议 浙江康恩贝制药股份有限公司 浙江康恩贝制药股份有限公司(以下简称"公司")第十一届董事会薪酬与考核委 员会 2025 年第三次会议于 2025 年 11 月 5 日以通讯方式召开。会议通知于 2025 年 10 月 31 日以书面、传真、电子邮件方式送达董事会薪酬与考核委员会各成员。会议应参 加审议表决董事 3人,实际参加审议表决董事 3人。会议的召开符合《公司法》、《公 司章程》的规定。 会议审议了有关议案,经书面表决通过决议如下: 一、审议通过《关于注销 2022年股票期权激励计划部分股票期权的议案》。表决 情况:同意3票,反对0票,弃权0票。 根据中国证监会《上市公司股权激励管理办法》《浙江康恩贝制药股份有限公司 2022 年股票期权激励计划(草案)》的相关规定以及公司 2022 年第二次临时股东大 会有关决议的授权,鉴于截至目前,公司 2022年股票期权激励计划(以下简称"本 次激励计划"）的激励对象中有人员因退休、离职等原因不再具备激励对象资格和行 权条件,以及经统计首次授予股票期权第二个行权期、预留授予股票期权第一个行权 期对应考核年度激励 ...

Core Viewpoint - Kang En Bei (600572.SH) announced a significant reduction in shareholding by Hu Jiqiang and Kang En Bei Group, impacting their ownership percentage in the company [1] Group 1: Shareholding Changes - From September 4 to November 6, 2025, Hu Jiqiang and Kang En Bei Group reduced their shares by a total of 23.76 million shares, with average selling prices of 4.58 CNY/share and 4.63 CNY/share respectively [1] - The total reduction accounted for 0.941% of the company's total share capital as of November 5, 2025 [1] - Following the reduction, the combined shareholding of Hu Jiqiang and Kang En Bei Group decreased from 351,986,156 shares to 328,224,556 shares, lowering their ownership percentage from 13.944% to 12.992% [1]

Core Viewpoint - The announcement reveals that Hu Jiqiang and Kang En Bei Group have reduced their shareholding in the company, indicating a strategic decision to decrease their stake without significantly impacting company governance or operations [1] Group 1: Shareholding Reduction - From September 4 to November 6, 2025, Hu Jiqiang and Kang En Bei Group collectively reduced their shares by 23.76 million shares, accounting for 0.941% of the company's total share capital [1] - The combined shareholding percentage of both parties decreased from 13.944% to 12.992%, with the change in equity reaching a 1% threshold [1] - Prior to this announcement, Kang En Bei Group had planned to reduce its holdings by up to 25.24 million shares between September 8 and December 7, 2025, and as of the announcement date, this plan had not been fully executed [1] Group 2: Impact on Company - The share reduction is stated to have no significant impact on the company's governance and operations [1] - There will be no change in the controlling shareholder or actual controller as a result of this share reduction [1]

浙江康恩贝制药股份有限公司 2025年第一次临时股东大会 会 议 材 料 二О二五年十一月十三日 浙江康恩贝制药股份有限公司 2025 年第一次临时股东大会会议材料 浙江康恩贝制药股份有限公司 2025 年第一次临时股东大会 议 程 主持人：姜毅董事长 时间：2025 年 11 月 13 日 地点：杭州市滨江区滨康路 568 号康恩贝中心 2 楼会议室 | 序 | 号 | 内 容 | 报告人 | | --- | --- | --- | --- | | 1 | | 审议《关于修订<公司章程>并办理工商变更登记事项的议 案》 | 金祖成 | | 2 | | 审议《关于修改<公司股东会议事规则>的议案》 | 金祖成 | | 3 | | 审议《关于修改<公司董事会议事规则>的议案》 | 金祖成 | | 4 | | 审议《关于修改<公司关联交易制度>的议案》 | 金祖成 | 1 浙江康恩贝制药股份有限公司 2025 年第一次临时股东大会会议材料 议案一 浙江康恩贝制药股份有限公司 关于修订《公司章程》并办理工商变更登记事项的议案 各位股东： 根据公司 2024 年度股东大会做出的同意注销回购专用账户股份的决议，并经通 ...

Core Insights - The company reported a revenue of 4.976 billion yuan for the first three quarters of 2025, a year-on-year increase of 1.27%, and a net profit attributable to shareholders of 584 million yuan, up 12.65% year-on-year [1] - In Q3 2025, the company achieved a revenue of 1.617 billion yuan, representing a 10.42% year-on-year growth, and a net profit of 230 million yuan, which is a significant increase of 69.11% year-on-year [1] - The company is focusing on enhancing cash flow management and operational efficiency, with a net operating cash flow increase of 16% year-on-year [1] Revenue Breakdown - The traditional Chinese medicine segment generated 2.676 billion yuan in revenue for Q1-Q3 2025, a growth of 5.73% year-on-year [2] - The specialty chemical drug segment reported a revenue of 1.720 billion yuan, a decline of 7.16% year-on-year, primarily due to the impact of centralized procurement [2] - The specialty health consumer products segment achieved a revenue of 485 million yuan, growing by 12.41% year-on-year [2] Product Performance - The company saw significant growth in key products, with the Changyanning series growing over 25% year-on-year through innovative marketing strategies [2] - Health product series increased over 13% year-on-year due to participation in industry standard formulation and clinical trials [2] - The Qiekan series and Zhixinfen both experienced over 9% growth year-on-year through brand activities and academic initiatives [2] R&D and Innovation - The company invested 184 million yuan in R&D during the first three quarters of 2025, focusing on innovative drug development and product lifecycle extension [3] - Several new drugs received approval, including two new traditional Chinese medicine products and multiple generic drug production licenses [3] - The company is enhancing the clinical and academic value of its core products through various research initiatives [3] Strategic Planning - The company is developing a five-year strategic plan to guide future growth and is actively seeking acquisition opportunities in innovative drugs and health consumer products [4] - The strategic plan aims to create a closed-loop management system to ensure effective execution [4] - Revenue growth projections for 2025-2027 are estimated at 3.9%, 6.0%, and 5.9%, respectively, with net profit growth of 4.6%, 5.2%, and 5.3% [4]

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 5.43 CNY over the next six months [5]. Core Insights - The company reported a steady performance in the first three quarters of 2025, achieving a revenue of 4.976 billion CNY, a year-on-year increase of 1.27%, and a net profit attributable to shareholders of 584 million CNY, up 12.65% [1]. - The company is actively formulating its "15th Five-Year Plan" to outline its strategic direction and growth opportunities, including potential mergers and acquisitions in the pharmaceutical sector [7]. Financial Performance - In Q3 2025, the company achieved a revenue of 1.617 billion CNY, representing a year-on-year growth of 10.42%, and a net profit of 230 million CNY, which is a significant increase of 69.11% [1]. - The operating cash flow for the first three quarters increased by 16% year-on-year, indicating improved operational efficiency [1]. Business Segments - The traditional Chinese medicine segment generated 2.676 billion CNY in revenue, up 5.73% year-on-year, while the specialty health products segment saw a revenue increase of 12.41% to 485 million CNY [2]. - The specialty chemical drug segment experienced a decline of 7.16% in revenue, primarily due to the impact of centralized procurement [2]. Research and Development - The company invested 184 million CNY in R&D during the first three quarters of 2025, focusing on innovative drug development and enhancing existing product lines [3]. - Several new drug approvals were achieved, including two new traditional Chinese medicine products and multiple generic drug approvals [3]. Future Projections - Revenue growth is projected at 3.9%, 6.0%, and 5.9% for 2025, 2026, and 2027 respectively, with net profit growth expected at 4.6%, 5.2%, and 5.3% during the same period [7].

Core Insights - 康恩贝's stock price increased by 2.19% on October 31, reaching 4.66 CNY per share, with a trading volume of 275 million CNY and a market capitalization of 11.766 billion CNY [1] - The company reported a year-to-date stock price increase of 3.23%, with a 4.25% rise over the last five trading days and a 6.88% increase over the last 20 days [1] - For the period from January to September 2025, 康恩贝 achieved a revenue of 4.976 billion CNY, reflecting a year-on-year growth of 1.27%, and a net profit attributable to shareholders of 584 million CNY, up 12.65% year-on-year [2] Financial Performance - 康恩贝's main business revenue composition includes 52.80% from traditional Chinese medicine, 35.68% from specialty chemical drugs, 9.56% from specialty health products, and 1.30% from other supplementary products [1] - Cumulative cash dividends paid by 康恩贝 since its A-share listing amount to 3.727 billion CNY, with 1.267 billion CNY paid out in the last three years [3] Shareholder Structure - As of September 30, 2025, 康恩贝 had 86,700 shareholders, a decrease of 3.48% from the previous period, with an average of 29,037 circulating shares per shareholder, an increase of 1.20% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 50.739 million shares, an increase of 23.964 million shares from the previous period [3]